Peter C Adamson
Overview
Explore the profile of Peter C Adamson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
4841
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Greengard E, Mosse Y, Liu X, Minard C, Reid J, Voss S, et al.
Cancer Chemother Pharmacol
. 2020 Oct;
86(6):829-840.
PMID: 33095287
Purpose: This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors...
12.
Pearson A, Stegmaier K, Bourdeaut F, Reaman G, Heenen D, Meyers M, et al.
Eur J Cancer
. 2020 Sep;
139:135-148.
PMID: 32992153
The fifth multistakeholder Paediatric Strategy Forum focussed on epigenetic modifier therapies for children and adolescents with cancer. As most mutations in paediatric malignancies influence chromatin-associated proteins or transcription and paediatric...
13.
Pearson A, Zwaan C, Kolb E, Karres D, Guillot J, Kim S, et al.
Eur J Cancer
. 2020 Jul;
136:116-129.
PMID: 32688206
Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major...
14.
Auletta J, Adamson P, Agin J, Kearns P, Kennedy S, Kieran M, et al.
Pediatr Blood Cancer
. 2020 Jun;
67(9):e28435.
PMID: 32558190
A diverse panel of pediatric cancer advocates and experts, whose collective experience spans the continuum of international academic medicine, industry, government research, and cancer advocacy, recently discussed challenges for pediatric...
15.
Minard-Colin V, Auperin A, Pillon M, Burke G, Barkauskas D, Wheatley K, et al.
N Engl J Med
. 2020 Jun;
382(23):2207-2219.
PMID: 32492302
Background: Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. Methods: We...
16.
Blaes A, Adamson P, Foxhall L, Bhatia S
JCO Oncol Pract
. 2020 Apr;
16(8):447-450.
PMID: 32267803
No abstract available.
17.
18.
Yohe M, Heske C, Stewart E, Adamson P, Ahmed N, Antonescu C, et al.
Pediatr Blood Cancer
. 2019 Jun;
66(10):e27869.
PMID: 31222885
Overall survival rates for pediatric patients with high-risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS,...
19.
LaRiviere M, Avery R, Dolan J, Adamson P, Zarnow D, Xie Y, et al.
Pract Radiat Oncol
. 2019 Apr;
9(4):226-230.
PMID: 30978466
No abstract available.
20.
Miller T, Fisher B, Getz K, Sack L, Razzaghi H, Seif A, et al.
Pediatr Blood Cancer
. 2019 Apr;
66(7):e27747.
PMID: 30968531
Background: Adverse events (AEs) on Children's Oncology Group (COG) trials are reported manually by clinical research assistants (CRAs). The Common Terminology Criteria for Adverse Events (CTCAE) was developed to provide...